Pipeline
Qu’s SSIs are uniquely positioned to treat and prevent cancer, chronic inflammatory diseases, and metabolic disease in a targeted organ.
Dr. Hal Gunn, CEO
SSI Pipeline: Advancing Clinical Programs Across Multiple Disease Areas
Therapeutic Area
SSI
Indication
Pre-clinical
Phase I
Phase II
Phase III
oncology
PERIOP-06 Study (RCT)
SSI
QBECO
Indication
Colon cancer
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBKPN
Indication
Lung Cancer
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBECO
Indication
Pancreatic cancer
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBECO
Indication
Ovarian Cancer
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBSAU
Indication
Melanoma
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBSAU
Indication
Breast Cancer
Pre-clinical
Phase I
Phase II
Phase III
immunosenescence
RESILIENCE Study (RCT)
SSI
QBKPN
Indication
Immunosenescence
Pre-clinical
Phase I
Phase II
Phase III
chronic inflammatory diseases
SSI
QBECO
Indication
Crohn's Disease (CD)
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBECO
Indication
Ulcerative Colitis (UC)
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBKPN
Indication
Chronic Obstructive Pulmonary Disease
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBKPN
Indication
Asthma
Pre-clinical
Phase I
Phase II
Phase III
Near Term Value Driving Milestones
Qu Biologics is actively enrolling participants in two randomized, double-blind, placebo-controlled clinical studies in immunosenescence (immune dysfunction with aging) (n=72)—the RESILIENCE Study—and in patients with late-stage colon cancer undergoing section of liver metastases (n=115)—the PERIOP-06 Study—with transformational milestones anticipated in Q1 2025.